Compare Eli Lilly And Co (LLY) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs J M Smucker Co — how do they compare? Eli Lilly And Co trades at $1,221.42 (market cap $1.08T), while J M Smucker Co trades at $117.46 (market cap $12.54B). The key difference: Eli Lilly And Co is far larger — about 86.1× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.82%). Which is the better fit depends on your goals.
| LLY | SJM | |
|---|---|---|
Market Cap | $1.08T | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $126.35 |
52-Week Low | $639.43 | $89.53 |
Enterprise Value | $1.13T | $19.57B |
Dividend Yield | 0.57% | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
SJM trades at $118.84, up 0.65% today, with a bullish technical signal and support near $117. The company reported revenue of $8.73B in 2025 but a net loss of -$1.23B, though recent quarters show earnings beats. Analyst consensus is a Buy with a $125.11 price target, and the dividend was recently increased to $1.12 per share, marking 25 consecutive years of growth.
Outlook is mixed: strong cash flow and dividend growth support income investors, but negative margins and high debt pose risks. Upside depends on cost controls and Uncrustables growth offsetting sales declines. The stock offers value at a P/E of 22.05 but faces execution challenges in a competitive consumer staples market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
